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Abstract
Background: The widespread availability of cannabis 
raises concerns regarding its effect on driving perfor-
mance and operation of complex equipment. Currently, 
there are no established safe driving limits regarding 
∆9-tetrahydrocannabinol (THC) concentrations in blood or 
breath. Daily cannabis users build up a large body burden 
of THC with residual excretion for days or weeks after the 
start of abstinence. Therefore, it is critical to have a sensi-
tive and specific analytical assay that quantifies THC, the 
main psychoactive component of cannabis, and multiple 
metabolites to improve interpretation of cannabinoids in 
blood; some analytes may indicate recent use.
Methods: A liquid chromatography tandem mass 
spectrometry (LC-MS/MS) method was developed to 
quantify THC, cannabinol (CBN), cannabidiol (CBD), 
11-hydroxy-THC (11-OH-THC), (±)-11-nor-9-carboxy-Δ9-
THC (THCCOOH), (+)-11-nor-Δ9-THC-9-carboxylic acid 
glucuronide (THCCOOH-gluc), cannabigerol (CBG), and 
tetrahydrocannabivarin (THCV) in whole blood (WB). WB 
samples were prepared by solid-phase extraction (SPE) 
and quantified by LC-MS/MS. A rapid and simple method 
involving methanol elution of THC in breath collected in 
SensAbues® devices was optimized.
Results: Lower limits of quantification ranged from 0.5 to 
2 μg/L in WB. An LLOQ of 80 pg/pad was achieved for THC 
concentrations in breath. Calibration curves were linear 
(R2 > 0.995) with calibrator concentrations within ±15% of 
their target and quality control (QC) bias and imprecision 
≤15%. No major matrix effects or drug interferences were 
observed.
Conclusions: The methods were robust and adequately 
quantified cannabinoids in biological blood and breath 
samples. These methods will be used to identify cannabi-
noid concentrations in an upcoming study of the effects of 
cannabis on driving.
Keywords: breath; cannabis; LC-MS/MS; mass spectro-
metry; THC; whole blood.
Introduction
Cannabis is available for medicinal purposes in many 
states. An expert review from the National Academies 
of Science, Engineering, and Medicine (2017) found that 
there was conclusive or substantial evidence for the use 
of cannabis and/or cannabinoids for certain conditions 
(e.g. chronic pain, emesis, spasticity due to multiple scle-
rosis), with mixed or limited evidence for many other 
conditions [1]. Whole-plant-based and non-prescription 
products still dominate the market, and cannabis as a 
medicine remains controversial [2]. Furthermore, as more 
cannabinoid pharmacotherapies are identified, the need 
for assays to accurately measure cannabinoid concentra-
tions will increase.
Support for recreational legalization of cannabis 
is growing [3]. With this comes concerns regarding the 
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impact of acute cannabis use on safety and driving per-
formance. According to the National Roadside Study of 
Alcohol and Drug Use by Drivers, ∆9-tetrahydrocannabi-
nol (THC) was the most frequently detected illicit drug in 
drivers [4]. THC impairs learning [5] and driving-related 
functions, such as reaction time and tracking ability 
[6]. This impairment is dose-dependent and can last for 
several hours [6, 7].
There are several challenges in determining impair-
ment while driving under the influence of cannabis 
(DUIC). The time between a traffic stop or motor vehicle 
crash and a blood draw is typically 1.5–4.5 h [8, 9], while 
THC blood concentrations are >90% cleared within 1.4 h 
[10]. Therefore, measured THC concentrations likely will 
not reflect concentrations at the time of the incident. 
Blood is currently the standard matrix for toxicological 
interpretations but a non-invasive matrix such as oral fluid 
or breath may enable more timely roadside collections. In 
addition, blood THC concentrations do not correlate with 
cognitive effects [11]. Maximum THC concentrations are 
typically observed within 15 min of the start of smoking 
but the subjective “high” and objective impairment can 
last for several hours [12]. Finally, the clearance rate of 
THC depends on the frequency of cannabis use. THC can 
be detected (LLOQ 0.25–0.5 μg/L) for several weeks in the 
blood of chronic users [13], but only for days in occasional 
users [14].
Given the tenuous relationship between blood THC 
concentrations and impairment, it may prove fruitful 
to examine additional THC metabolites. We thus opti-
mized and validated a liquid chromatography tandem 
mass spectrometry (LC-MS/MS) method that could 
simultaneously quantify multiple cannabinoids and 
metabolites, including THC, 11-hydroxy-THC (11-OH-THC), 
(±)-11-nor-9-carboxy-Δ9-THC (THCCOOH), (+)-11-nor-Δ9-
THC-9-carboxylic acid glucuronide (THCCOOH-gluc), can-
nabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), 
and tetrahydrocannabivarin (THCV), in whole blood (WB) 
in a single 5-min run. Furthermore, the detection of THC 
from breath specimens was validated.
Materials and methods
Chemicals, materials, and blank matrices
Stocks of 1 mg/mL of CBD, THC, CBN, 11-OH-THC, CBG, THCV, THCA-
A, and THCCOOH-D3 as well as 100 μg/mL solutions of THCCOOH, 
THCCOOH-gluc, CBD-D3, THC-D3, CBN-D3, and 11-OH-THC-D3 were 
purchased from Cerilliant (Round Rock, TX, USA). A 10-μg/mL THC-
gluc stock was obtained from ElSohly (Oxford, MS, USA).
Optima LC/MS grade acetonitrile, methanol, 2-propanol, formic 
acid (FA), and ammonium acetate were obtained from Fisher Sci-
entific (Hampton, NH, USA). Oasis PRiME HLB 96-well solid-phase 
extraction (SPE) plates with 30 mg sorbent/well, 96-well collection 
plates, quick-load glass inserts, silicone/PTFE-treated 96-well square 
plug cap mats, and amber max recovery autosampler vials were 
acquired from Waters (Milford, MA, USA). Borosilicate glass tubes 
were from Fisher Scientific and 18.2 MΩ-cm water was dispensed 
from a Siemens PureLab Ultra purification system.
Blank WB was created by mixing acid citrate dextrose (ACD)-
packed red blood cells with ABO-compatible plasma and confirming 
the absence of detectable cannabinoids. Breath matrix consisted of 
an unused SensAbues® electret filter material (“pad”) cut into 28 cm2 
squares to match the intake surface area of the SensAbues® collec-
tion device.
Preparation of standards
Calibrators were prepared in methanol using class A glass volumetric 
pipettes and glass volumetric flasks. All stock and working calibra-
tors were stored at −20 °C.
Whole blood standards: Concentrated methanolic stocks of 
10,000  μg/L (lacking THC-gluc) and 1000 μg/L containing CBN, 
CBD, THC, 11-OH-THC, CBG, THCV, THCA-A, THCCOOH, THCCOOH-
glu, and THC-gluc were prepared by mixing and diluting the com-
mercially available standards. Parallel dilutions of the 1000-μg/L 
stock were used to formulate the remainder of the working standards 
in methanol. Final concentrations were 10,000 (lacking THC-gluc), 
1000, 500, 100, 20, 10, and 5 μg/L. Working standards were added to 
blank WB at a 1:10 dilution to give final concentrations of 1000, 100, 
50, 10, 2, 1, and 0.5 μg/L, respectively.
Breath standards: Parallel dilutions of a 100-μg/mL stock of THC 
created working standards at concentrations of 10,000, 4000, 100, 
20, and 5 μg/L in methanol. To create a calibration curve, 25 μL of the 
5-, 20-, 4000-, and 10,000-μg/L standards and 50 μL of the 10,000-
μg/L standard were pipetted directly onto unused SensAbues® pads 
for final amounts of 125, 500, 100,000, 250,000, and 500,000 pg/pad, 
respectively.
Internal standard (IS): A concentrated deuterium-labeled stock 
solution was prepared by mixing and diluting THC-D3, THCCOOH-
D3, CBD-D3, CBN-D3, and 11-OH-THC-D3 in methanol. Final concen-
trations were 100 μg/L for all compounds except CBD-D3. CBD-D3 
was added at 10 μg/L because 100 μg/L caused interference, pre-
senting as a shoulder on the CBG qualifier ion peak (Supplementary 
Figure 1).
The IS for CBN, CBD, THC, 11-OH-THC, and THCCOOH were the 
corresponding deuterated compounds. CBD-D3 was the IS for CBG 
and THCA-A. 11-OH-THC-D3 was the IS for THC-gluc and THCV. THC-
COOH-D3 was the IS for THCCOOH-gluc due to the presence of a dou-
ble peak in THCCOOH-gluc-D3 (Supplementary Figure 2).
IS was added to WB at a 1:10 dilution, resulting in final concen-
trations of 1 μg/L for CBD-D3 and 10 μg/L for all others. For breath 
analysis, only THC was monitored. Twenty-five microliters of IS was 
spiked into a clean SensAbues® device containing a pad for a final 
concentration of 250 pg THC-D3/pad.
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Preparation of quality control (QC) material
QC working stocks were made by parallel dilution of a 1000-μg/L 
stock, as described for the calibrators, except using different lots for 
all compounds except for THC-gluc where only one lot was commer-
cially available. At least one set of QCs at three different concentra-
tions were included in every batch. The concentration of WB working 
QCs after validation were 33.3, 100, and 833 μg/L. These were diluted 
1:10 into WB for final concentrations of 3.3, 10.0, and 83.3 μg/L, 
respectively. The concentration of breath QC stocks were 6.0, 60.0, 
and 6000 μg/L. Pads were spiked with 25 μL for final concentrations 
of 150, 1500, and 150,000 pg THC/pad, respectively.
Sample collection
Participants provided blood and breath samples as part of a larger 
study examining cannabis-related driving impairment approved by 
the University of California, San Diego Human Research Protections 
Program (IRB # 160641). Consenting volunteers (n = 5) were given a 
joint containing 13.4% THC procured from the National Institute on 
Drug Abuse Drug Supply Program. Blood and breath samples were 
collected prior to and ~10  min after smoking cessation. Venous 
blood was drawn from the arm in sodium fluoride (NaF) vacutainer 
tubes. WB was transferred to cryovials and stored at −20 °C for up 
to 3 months until analysis [15]. Breath samples were collected over 
a 3-min period using a SensAbues® device containing a pad to trap 
aerosol breath (AB, Sweden). Mouthpieces were discarded, and the 
devices containing collection pads were capped and stored at −20 °C 
for up to 6 months until analysis [16].
Sample processing
Whole blood: Calibrators and QCs were prepared by fortifying cali-
brators or QCs (20 μL) into 200 μL blank WB in borosilicate tubes. 
Blank and volunteer WB (200 μL) were added to corresponding tubes 
and fortified with 20 μL methanol. IS (20 μL) was added to all tubes 
except one of two blank tubes, resulting in a “blank” and “blank + 
IS”. Proteins were precipitated by adding 500 μL ice-cold acetoni-
trile with 0.1% FA dropwise into each tube while vortexing. Samples 
were centrifuged at 1962  ×  g for 10 min. Supernatants were poured 
into new tubes, diluted with 1.1 mL 18 MΩ water, and loaded onto an 
SPE plate. SPE was performed using a positive pressure apparatus 
(Waters Positive Pressure-96). Samples were loaded onto the sorb-
ent material at low pressure (10 psi) for 5 min. Next, samples were 
washed twice with 500 μL 25% methanol. Samples were eluted twice 
with 100 μL 90:10 acetonitrile:isopropanol and twice with 100 μL 
50:50 acetonitrile:methanol with 2% FA into a 96-well plate with 
glass inserts. Samples were dried with 40 °C N2 gas (Porvair Sciences 
MiniVap), reconstituted in 200 μL 50% acetonitrile with 0.1% FA, and 
capped with a cap mat. Plates were vortexed (Multi-tube vortexer, 
Fisher Scientific), centrifuged at 1962 × g for 10 min, and loaded into 
an autosampler.
Breath: A pad was placed inside clean SensAbues® devices for the 
calibrators, QCs, blank, and blank + IS. These were placed on top 
of borosilicate tubes with the device neck inside each tube. Devices 
from volunteers were also placed into tubes. Working IS (25 μL) was 
added to each device except for the blank. Next, QCs and calibrators 
were added to the corresponding devices. The devices were dried 
at room temperature for 10  min. Pads were pushed into the neck 
of the device with a clean wooden applicator. Samples were eluted 
twice with 2.5 mL of methanol over 10 min. Residual methanol was 
squeezed from the device using a pipette bulb affixed on top of each 
device. Samples were mixed and 1.5 mL was transferred to each of 
the two max recovery vials (one for processing, one for storage). 
Vials were dried under nitrogen at 60 °C for 25 min, re-suspended 
with 200  μL 50% acetonitrile with 0.1% FA, and loaded into the 
 autosampler.
Liquid chromatography (LC)
LC was performed in a similar manner to a previously described 
method [17]. Briefly, a Waters Acquity i-class UPLC equipped with a 
column heater (40 °C) was utilized. Full-loop 10 μL injections were 
separated on a BEH C18 column (2.1 × 50 mm, 1.7 μm particles) with a 
BEH C18 VanGuard pre-column (2.1 × 5 mm, 1.7 μm particles). Separa-
tion was performed with a 0.4 mL/min flow rate using mobile phase 
A (MPA) consisting of 5 mM ammonium formate with 0.1% FA and 
mobile phase B (MPB) consisting of acetonitrile with 0.1% FA. The 
method starts with 50% MPB for 30  s followed by a 3.5-min linear 
gradient increasing to 90% MPB. The column was washed for 15 s at 
90% MPB and then re-equilibrated with initial conditions for 45  s. 
The total run time was 5 min/sample.
Mass spectrometry (MS)
As described previously [17], the LC system was coupled to a Waters 
TQS-micro tandem quadrupole MS with an electrospray ionization 
source. All compounds were analyzed in a positive ionization mode 
with the exception of THCCOOH-gluc, which required negative ioni-
zation. Transition ions were collected by scheduled multiple reaction 
monitoring using previously described parameters [17]. Concentra-
tions were calculated by dividing quantifier transition ion peak 
areas by IS peak areas and quantified against the calibration curve 
included with each batch. A representative chromatogram of all 
quantifier ions and deuterated ISs from a WB calibrator is displayed 
in Figure 1.
Method validation
Method validation was done in accordance with the Clinical and 
Laboratory Standards Institute (CLSI) C62-A guidelines for LC-MS/
MS. Experimental design was modified from the CLSI EP05-A3 guide-
lines for the evaluation of the precision of quantitative measurement 
procedures.
Sensitivity and detection criteria: The LLOQ was determined as the 
lowest concentration with an acceptable peak shape, signal-to-noise 
ratio (S/N ≥ 10), accuracy (% bias) and imprecision (% CV) within 
20%, and a quantifier-to-qualifier ratio within 20% of the mean cali-
brator ratio. Peaks for compounds with a corresponding deuterated 
IS (THC, 11-OH-THC, THCCOOH, CBN, and CBD) were identified based 
on a relative RT of 1.01 ± 0.02. Compounds without a corresponding 
Authenticated | jachubbard@gmail.com author's copy
Download Date | 10/14/19 3:43 AM
4      Hubbard et al.: LC-MS/MS detection of cannabinoids in whole blood and breath
deuterated IS were identified by RTs matching within ±0.02 min of 
the calibrators. An exception to this was THCCOOH-gluc, which 
exhibited an RT shift of ~0.06 min in biological samples compared 
to commercially available calibrators due to isomeric differences 
( Supplementary Figure 2).
Linearity: Calibration curves were established with five to seven 
calibrators per compound in WB and five calibrators in breath. A 
line was fitted using a least-squares regression with a 1/x weighting 
factor. Linearity was validated with five replicates of all calibrators 
analyzed on different days. Acceptability criteria required that all 
calibrators except the LLOQ quantify within ±15% of the target con-
centration; the LLOQ was required to quantify within ±20%. Impre-
cision criteria for all calibrators was ≤20% CV and the coefficient 
of determination (R2) was required to be ≥0.995. For each batch, a 
maximum of one calibrator was allowed to be excluded from the 
curve for cause.
QC bias and imprecision: The QC bias and inter-day imprecision 
were determined using two concentrations of QC each day for 20 days 
(n = 20 per QC). The intra-day imprecision was assessed with six rep-
licates of two QC concentrations within the same run. Imprecision 
was required to be ≤20%. QC values were reassigned based on mean 
concentrations obtained during validation.
Process efficiency and matrix effects: The total process efficiency 
(PE) was determined by comparing area counts of blank matrix forti-
fied with low QC, and IS prior to sample processing were compared to 
area counts of “neat” sample containing low QC and IS in the elution 
solvent [18]. At least three replicates of three concentrations across 
the analytical measuring range were used for both sets. For WB, this 
was done in both ACD and NaF blood to determine if calibrators cre-
ated using ACD blood would accurately quantify analytes in NaF 
blood.
WB in ACD and NaF tubes and breath samples were collected 
from 10 drug-free volunteers. The matrix effect was quantified by 
spiking samples with the low QC prior to processing. Recovered 
 concentrations were then compared to the low QC mean established 
in validation.
Drug interferences: The blank matrix fortified with low QC was 
spiked with either methanol or one of five pools containing supra-
physiological concentrations of 10 commonly prescribed or abused 
drugs [17]. Lack of interference was defined as ≤20% bias in the quan-
tification of the low QC concentration in the presence of the different 
potential interferents.
Autosampler stability and carryover: The stability of samples stored 
in the autosampler (10 °C) was assessed by comparing the concentra-
tions of QCs and volunteer samples obtained during the initial run 
and those obtained 24, 48, 72, and 96 h later. Samples were consid-
ered stable if the concentration was quantified within 20% of the ini-
tial concentration.
Carryover was investigated by injecting a blank + IS before and 
immediately after the highest calibrator. The blank was visually 
inspected for any identifiable peak. The criteria for acceptable car-
ryover was a concentration <20% of the lowest calibrator.
Results
Limits of detection, accuracy, and linearity
A representative chromatogram of each reported com-
pound at the LLOQ is shown (Figure 2). The LLOQs, ULOQs, 
calibration accuracy range, and mean R2 value are listed in 
Table 1. LLOQs in WB ranged from 0.5 to 2 μg/L. The LLOQ 
for THC in breath was 80 pg/pad. THC-gluc and THCA-A 
in WB did not pass the validation criteria (see following 
Figure 1: Total ion chromatogram of a 10-μg/L calibrator in whole blood.
Each peak is labeled with the corresponding cannabinoid(s). Signal intensity (y-axis) is plotted against retention time (x-axis). All were 
chromatographically resolved with the exception of CBG, CBD, and THCV.
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text). For all other compounds, linearity throughout the 
measurable range was validated.
QC bias and imprecision
All QCs were within 8% of the target concentration except 
for THCV in WB, which exhibited a 14.8% bias for QC2 
(Table 2). The intra-day imprecision ranged from 1 to 8.6% 
for all cannabinoids. The inter-day imprecision was slightly 
higher for most compounds and ranged from 4.3 to 12.5%.
Process efficiency
PE was determined in ACD and NaF anticoagulated blood 
(Table 3). Similar efficiencies were obtained in both blood 
types with the exception of CBN and THC (>20% differ-
ence). Their corresponding ISs showed similar differences 
between the two blood types and therefore corrected for 
matrix effects. However, CBN-D3 and THC-D3 could not be 
used as an IS for any other compound due to this issue. 
Similar total PEs were observed between THC and THC-D3 
in the breath method (Table 3).
Figure 2: Representative extracted ion chromatograms of the quantifier transition ions for all cannabinoids at the lower limit of 
quantification.
The percent signal intensity (y-axis) is plotted against retention time (x-axis). The cannabinoids shown, from left to right, include THCCOOH-
gluc, 11-OH-THC, THCCOOH, CBG, CBD, THCV, CBN, and THC in whole blood, and THC in breath. The lower limit of quantification ranged from 
0.5 to 2 μg/L in blood and was 80 pg/pad in breath.
Table 1: Linearity and limits of quantification.
Cannabinoid   LLOQ, μg/L  ULOQ, μg/L   Calibrator %
accuracy range
  Mean R2 of 
calibration curve
THCCOOH-gluc   2.0   1000   93–108  0.9997
11-OH-THC   1.0   100   88–110  0.9996
THCCOOH   1.0   1000   92–109  0.9997
CBG   1.0   100   90–111  0.9993
CBD   0.5   100   91–110  0.9988
THCV   0.5   100   86–112  0.9990
CBN   0.5   1000   91–114  0.9997
THC (blood)   0.5   1000   83–111  0.9992
THC (breath)   80 pg/pad   500,000 pg/pad   85–114  0.9985
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Matrix effects and drug interferences
To assess the matrix effect, samples were spiked with 3.3 
μg/L QC and the recovered concentration was compared 
to the expected values (Table 4). All biases were <20% 
with the exception of THC-gluc (−21%) and THCA-A (53%) 
in blood. Due to this interference and a lack of deuter-
ated IS to correct for it, THC-gluc and THCA-A failed 
validation. Breath samples spiked with 150 pg/pad did 
not show a matrix effect. No drug interferences were 
observed (Table 5).
Autosampler stability and carryover
THC concentrations in processed breath remained stable 
for at least 96  h in the autosampler; all samples were 
re-quantified within 20% of the initial concentration. In 
WB, all cannabinoids were stable for at least 24 h. At 48 h 
post-extraction, all compounds except THCCOOH-gluc 
were stable. By 72 h, several compounds, including CBN, 
THC, and THCCOOH-gluc, were not quantifiable. Metha-
nolic calibrators and QCs were stable at −20 °C for at least 
2 years.
No carryover was observed for any cannabinoid in 
either matrix.
Authentic sample quantification before and 
after smoking
Concentrations of all compounds were measured prior to 
and after smoking in five volunteers as proof of concept 
that our method accurately measures THC and its metab-
olites in authentic samples (Table 6). THCCOOH and 
THCCOOH-gluc were detectable in WB of four of the five 
volunteers prior to smoking. After smoking, all cannabi-
noids except THCV and CBD were detected in WB. All 
participants had detectable levels of THC in breath after 
smoking.
Discussion
We describe a robust, validated method for the quantifica-
tion of eight cannabinoids in WB and THC in breath. The 
WB method expands on previously published approaches 
[19–24] and includes additional cannabinoids in a single 
Table 2: QC bias and imprecision.
Cannabinoid  
 
Bias, %  
 
Intra-day 
precision, % CV
 
 
Inter-day 
precision, % CV
QC 1   QC 2 QC 1   QC 2 QC 1   QC 2
THCCOOH-gluc  −1.7   −4.9   8.6   4.3   6.8   8.1
11-OH-THC   −5.1   −3.3   4.1   3.1   7.8   5.6
THCCOOH   −2.4   −3.1   5.0   3.6   6.1   5.8
CBG   −6.2   −7.9   4.4   1.0   5.5   12.5
CBD   −5.4   −0.8   3.8   3.0   6.0   4.3
THCV   −5.1   14.8   2.3   4.5   6.0   7.1
CBN   −4.2   −1.1   5.4   2.6   6.5   4.9
THC (blood)   −1.8   1.9   2.4   2.0   6.9   5.2
THC (breath)   −5.1   −7.7   4.7   7.5   8.9   5.0
Target concentrations for whole blood: QC 1 = 3.3 μg/L and QC 
2 = 3.3 μg/L. Target concentrations for breath: QC 1 = 150 pg/pad and 
QC 2 = 1500 pg/pad.
Table 3: Process efficiency for acid citrate dextrose (ACD) blood, 
sodium fluoride (NaF) blood, and breath.
 
 
Recovery, % 
 
% Difference
ACD  NaF (NaF − ACD)
Cannabinoid (blood)      
 THCCOOH-gluc   67.9  70.8  2.9
 11-OH-THC   67.4  81.0  13.6
 11-OH-THC-D3   59.4  70.2  10.8
 THCCOOH   76.1  80.9  4.8
 THCCOOH-D3   65.7  66.0  0.3
 CBG   62.1  68.1  6.0
 CBD   67.5  77.6  10.1
 CBD-D3   60.7  66.4  5.7
 THCV   78.4  86.6  8.2
 CBN   39.5  69.0  29.5
 CBN-D3   35.6  61.2  25.6
 THC   41.1  79.7  38.6
 THC-D3   33.3  68.4  35.1
Cannabinoid (breath)     –
 THC   52.0  –
 THC-D3   61.5  –
Table 4: Quantitative matrix interference between authentic 
samples and the corresponding blank matrix.
Cannabinoid Mean % bias
THCCOOH-gluc 6
THC-gluc −21
11-OH-THC 12
THCCOOH 5
CBG −1
CBD 7
THCV 17
CBN 9
THC (blood) 8
THCA-A 53
THC (breath) 7
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5-min run. The breath method offers a simplified, yet accu-
rate approach to process and quantify THC in breath. Our 
method quantifies THC and several cannabis metabolites 
in authentic human blood and breath samples. Together, 
these methods will aid in future cannabis therapeutic effi-
cacy and driving safety studies.
There is no agreement in the blood THC concentra-
tion that defines impairment. This contrasts with blood 
alcohol concentrations (BAC), for which concentra-
tions as low as 0.05%–0.08% are strongly correlated 
with impairment [25]. Portable breath analyzers are 
used as preliminary screens to estimate BAC. Given the 
invasive nature of blood draws and frequent collection 
delays, there is increasing interest in the detection of 
THC in an easily collected matrix, such as breath. THC 
concentrations in breath indicate recent use and may 
correlate with blood concentrations [26]. Furthermore, 
breath  concentrations are correlated with physiological 
changes such as change in pulse rate and pupil dia-
meter seen after smoking [27]. Therefore, breath could 
serve as an alternative matrix for roadside impairment 
assessment.
Other groups published methods to detect cannabi-
noids in breath. Beck and colleagues offered a method 
that required a 1-h incubation in a thermostatic bath at 
37 °C combined with two extraction procedures [28]. Here, 
we offered a simplified method that reduced turnaround 
time. A more recent method using azo coupling derivati-
zation offers sensitive detection with an LLOQ of 0.5 pg 
THC/mL [29]. Finally, a previously published method 
using the SensAbues® device measured THC concentra-
tions in breath ranging from 50.7 to 1170 pg/pad at a mean 
time of 53  min after smoking [16]. We observed much 
higher concentrations (≥88,595 pg/pad), likely because 
samples were collected ~10 min after smoking was com-
pleted, when THC concentrations in breath would be near 
maximal. This difference is unlikely due to oral fluid con-
tribution because retention of oral fluid by the trapping 
baffles integrated into the mouthpiece of the SensAbues® 
device was previously confirmed by the lack of α-amylase 
in samples eluted directly from the pad while kept inside 
the device [30]. Our goal was to validate a method with 
a quicker and simpler procedure that accurately quanti-
fies THC in breath. Our method offers a straightforward 
Table 5: Drug interferences expressed as percent bias compared to the methanol-spiked QC.
Cannabinoid Drug pool 1 Drug pool 2 Drug pool 3 Drug pool 4 Drug pool 5
THCCOOH-gluc 8.3 −1.0 −2.8 8.3 2.8
THC-gluc 15.9 5.3 6.8 11.4 9.1
11-OH-THC 9.4 6.5 9.4 9.4 12.5
THCCOOH 2.7 2.2 −8.1 −2.7 −5.4
CBG 16.7 −5.3 16.7 13.3 13.3
CBD 20.0 −3.1 13.3 13.3 13.3
THCV −2.1 −7.9 −6.3 −8.3 0.0
CBN 6.1 −1.1 6.1 9.1 15.2
THC (blood) 11.8 −2.2 8.8 8.8 8.8
THCA-A −2.1 −7.9 −12.1 6.1 6.1
THC (breath) 7.9 6.2 8.4 −5.4 6.4
Table 6: Proof-of-concept cannabinoid concentrations before and after smoking a joint containing 13.4% THC.
Cannabinoid Prior to smoking, μg/L Ten minutes after smoking cessation, μg/L
Median Range Median Range
THCCOOH-gluc 21.8 <LLOQ–275 24.7 <LLOQ–235
11-OH-THC <LLOQ <LLOQ–1.8 3.0 1.5–12.1
THCCOOH 9.8 <LLOQ–54.5 26.7 11–64.7
CBG <LLOQ <LLOQ 1.1 <LLOQ–1.6
CBD <LLOQ <LLOQ <LLOQ <LLOQ
THCV <LLOQ <LLOQ <LLOQ <LLOQ
CBN <LLOQ <LLOQ 4.9 1.1–7.3
THC (blood) <LLOQ <LLOQ–3.9 60.9 10.3–78.4
THC (breath) <LLOQ <LLOQ–242 pg/pad 163,000 pg/pad 88,595–279,000 pg/pad
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extraction protocol that does not require disassembling 
SensAbues® breath devices or derivatization while still 
achieving good analytical sensitivity.
During validation, THCA-A and THC-gluc exhibited 
significant matrix effects. Despite this, others have quan-
tified THCA-A [31] and THC-gluc [32] using LC-MS/MS in 
WB. Sorensen and colleagues removed interfering phos-
pholipids by filtration using a hybrid SPE-phospholipid 
plate containing a stationary phase with bonded zirco-
nia and successfully quantified THCA-A [31]. Disposable 
pipette extraction, instead of SPE, was previously used to 
extract and quantify THC-gluc in WB [32].
We noted an RT shift in THCCOOH-gluc peaks between 
human samples and calibrators during validation (Sup-
plementary Figure 2). Biological THCCOOH-gluc eluted at 
1.28 min and the analytical standard at 1.22 min. The THC-
COOH-gluc-D3 available from Cerilliant (T-080, ( ±)-cis-
11-Nor-9-carboxy-Δ9-THC-D3-glucuronide) produced 
two isomeric chromatographic peaks. When THCCOOH-
gluc-D3 was base hydrolyzed, it resulted in the forma-
tion of THCCOOH-D3 with a shifted RT compared to the 
THCCOOH-D3 standard. However, when THCCOOH-gluc 
was hydrolyzed, the resulting RT of THCCOOH matched 
its respective standard. Therefore, the biological form of 
THCCOOH-gluc is likely a different isomer than the com-
mercially available form [33].
The WB and breath methods developed here facilitate 
efficient detection of multiple cannabinoid metabolites. 
It will be used in randomized placebo-controlled trials 
examining the effect of cannabis on driving performance 
and improving the detection of impaired drivers as well as 
other studies.
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